INDUSTRY NEWS GLOBAL INDUSTRY INSIGHTS Your roundup of world news in the science industry
PRECI AND BIOPREDIC TO PARTNER ON IN-VITRO ASSAY SYSTEMS
Biotechnology company Preci has partnered with Biopredic International, a company specialising in the design and manufacture of human and animal in vitro assay systems to collaborate on the production of pooled suspension human hepatocytes. Under a license agreement, Biopredic
will leverage Preci’s expertise and production capacity in sourcing primary hepatocytes, and combine this with its own IP and know-how in cell pooling. The partnership will provide drug
metabolism and pharmacokinetics researchers with access to large batches of high-performing suspended pooled hepatocytes with extended longevity from multiple donors. Pooled suspension human
hepatocytes play a crucial role in assessing drug metabolism and hepatic clearance, providing a more representative understanding of human hepatic metabolism for predicting drug outcomes and assessing their impact on safety and eff icacy. Despite this, the limited culture
lifespan of pooled hepatocytes hinders long-term studies, potentially reducing metabolic competence with repeated use of the same batch. Anton Hanopolskyi, CEO, Preci,
said: “At Preci, we believe that increased diversity and availability of representative cell models will revolutionize the drug discovery landscape. This partnership strengthens our position in the human-derived assays market, providing our customers with access to high quality, reproducible assays, and we look forward to continuing to work with Biopredic to advance our translational models for use in drug metabolism and pharmacokinetics studies.”
6
www.scientistlive.com
CEO of Preci, Anton Hanopolskyi
MULTIPLEXING FEATURES WILL ALLOW COMPANIES TO PROCESS MULTIPLE DNA SAMPLES
A leading life-sciences company Mission Bio has introduced sample multiplexing features for its Tapestri Platform. These features enable the combination of several samples into a single run, reducing the per-sample costs for single-cell DNA and protein multiomic analysis by up to 60%, according to the company. By allowing researchers to simultaneously process multiple samples, the new features have been designed to off er biopharma companies opportunities for optimising product characterisation and drug development to provide academic researchers with the ability to scale critical single-cell insights, particularly in oncology and genome editing fi elds. This will lead to transformative advancements in health and disease management. “At Mission Bio, our goal is to empower more researchers to harness the advantages of single-cell multiomics to accelerate scientifi c discoveries, from academics using genome editing techniques for disease modeling to biopharma in the cell and gene therapy space,” said Anjali Pradhan, chief product offi cer, Mission Bio.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60
